132 related articles for article (PubMed ID: 11469719)
1. Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity.
Ben-Efraim S
Curr Drug Targets; 2001 Jun; 2(2):197-212. PubMed ID: 11469719
[TBL] [Abstract][Full Text] [Related]
2. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor.
Mokyr MB; Place AT; Artwohl JE; Valli VE
Cancer Immunol Immunother; 2006 Apr; 55(4):459-68. PubMed ID: 15965646
[TBL] [Abstract][Full Text] [Related]
3. Tumoricidal and immunomodulatory activities of drugs and implications for therapy of mice bearing a late stage MOPC-315 plasmacytoma.
Berko R; Seissman K; Colvin M; Bocian RC; Ben-Efraim S; Dray S
Int J Immunopharmacol; 1988; 10(7):825-34. PubMed ID: 3235239
[TBL] [Abstract][Full Text] [Related]
4. The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.
Ben-Efraim S; Shoval S; Ophir R
Cancer Immunol Immunother; 1986; 22(1):43-8. PubMed ID: 2939947
[TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy.
Dray S; Mokyr MB
Med Oncol Tumor Pharmacother; 1989; 6(1):77-85. PubMed ID: 2657252
[TBL] [Abstract][Full Text] [Related]
6. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
Gorelik L; Prokhorova A; Mokyr MB
Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
[TBL] [Abstract][Full Text] [Related]
7. Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.
Weiskirch LM; Baumgartel BA; Barker E; Mokyr MB
Cancer Immunol Immunother; 1991; 32(6):353-63. PubMed ID: 1901031
[TBL] [Abstract][Full Text] [Related]
8. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
9. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
Barker E; Mokyr MB
Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
[TBL] [Abstract][Full Text] [Related]
10. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome.
Gorelik L; Mokyr MB
Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194
[TBL] [Abstract][Full Text] [Related]
11. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
Takesue BY; Bartik MM; Mokyr MB
Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627
[TBL] [Abstract][Full Text] [Related]
12. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
Barker E; Mokyr MB
Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
[TBL] [Abstract][Full Text] [Related]
13. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
Mokyr MB; Barker E
Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
[TBL] [Abstract][Full Text] [Related]
14. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Mokyr MB
Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
[TBL] [Abstract][Full Text] [Related]
15. Classification of anticancer chemotherapeutic drugs according to their immunopotentiating activity.
Ben-Efraim S; Shoval S; Gal T; Ophir R
Anticancer Res; 1986; 6(4):801-5. PubMed ID: 2944475
[TBL] [Abstract][Full Text] [Related]
16. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
Mokyr MB; Kalinichenko T; Gorelik L; Bluestone JA
Cancer Res; 1998 Dec; 58(23):5301-4. PubMed ID: 9850053
[TBL] [Abstract][Full Text] [Related]
17. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
19. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
Bartik MM; Takesue BY; Mokyr MB
Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
[TBL] [Abstract][Full Text] [Related]
20. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells.
Sojka DK; Donepudi M; Bluestone JA; Mokyr MB
J Immunol; 2000 Jun; 164(12):6230-6. PubMed ID: 10843675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
